CoTherix Gets Approval For Inhaled PAH Drug Ventavis Jan. 4, 2005 Providing a new, less-invasive treatment option for pulmonary arterial hypertension patients, CoTherix Inc. received FDA approval for Ventavis, an inhaled product in-licensed from Schering AG in October 2003. (BioWorld Today)Read More
RSS